DBV Technologies enrols first patient in Phase III peanut allergy trial

French biopharmaceutical firm DBV Technologies has started patient enrolment in a Phase III EPITOPE clinical trial of Viaskin Peanut to treat peanut allergy in young children.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news